| __timestamp | Exelixis, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 23068000 | 116287000 |
| Thursday, January 1, 2015 | 33277000 | 136004000 |
| Friday, January 1, 2016 | 184902000 | 203017000 |
| Sunday, January 1, 2017 | 437411000 | 287023000 |
| Monday, January 1, 2018 | 827478000 | 393541000 |
| Tuesday, January 1, 2019 | 934678000 | 376095000 |
| Wednesday, January 1, 2020 | 951266000 | 467938000 |
| Friday, January 1, 2021 | 1382097000 | 504714000 |
| Saturday, January 1, 2022 | 1553153000 | 580017000 |
| Sunday, January 1, 2023 | 1757661000 | 523742000 |
| Monday, January 1, 2024 | 2168701000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, financial performance is a key indicator of a company's success. Over the past decade, Exelixis, Inc. and Supernus Pharmaceuticals, Inc. have been vying for dominance in gross profit generation. From 2014 to 2023, Exelixis has consistently outperformed Supernus, with a staggering 6600% increase in gross profit, peaking at $1.76 billion in 2023. In contrast, Supernus saw a more modest growth of 350%, reaching $580 million in the same year. This remarkable growth trajectory highlights Exelixis's strategic prowess in capitalizing on market opportunities and optimizing operational efficiencies. As the biotech industry continues to evolve, these financial insights provide a glimpse into the dynamic landscape where innovation and profitability go hand in hand.
Sanofi vs Supernus Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown
Gross Profit Comparison: Gilead Sciences, Inc. and Exelixis, Inc. Trends
Takeda Pharmaceutical Company Limited vs Supernus Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown
Incyte Corporation vs Supernus Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown
Gross Profit Trends Compared: Catalent, Inc. vs Exelixis, Inc.
Walgreens Boots Alliance, Inc. vs Supernus Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown
Exelixis, Inc. vs Arrowhead Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown
Who Prioritizes Innovation? R&D Spending Compared for Exelixis, Inc. and Supernus Pharmaceuticals, Inc.
Who Generates Higher Gross Profit? Exelixis, Inc. or Travere Therapeutics, Inc.
Grifols, S.A. vs Supernus Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown
Gross Profit Analysis: Comparing Alkermes plc and Supernus Pharmaceuticals, Inc.
MorphoSys AG vs Supernus Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown